Clinical Trial Update: Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial investigating digoxin immune Fab (AMAG-423) for severe preeclampsia in antepartum subjects was terminated after Phase 2/3 testing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Preeclampsia

Drugs mentioned

• AMAG-423 (digoxin immune Fab)

Snippet

Sponsor: AMAG Pharmaceuticals, Inc. | Conditions: Severe Preeclampsia | Phase 2, Phase 3 | Status: TERMINATED